3,4-Dihydro-2h-Pyrrolium-5-Carboxylate

Identification

Name
3,4-Dihydro-2h-Pyrrolium-5-Carboxylate
Accession Number
DB02838  (EXPT00141)
Type
Small Molecule
Groups
Experimental
Description
Not Available
Structure
Thumb
Synonyms
Not Available
Categories
Not Available
UNII
Not Available
CAS number
Not Available
Weight
Average: 113.1146
Monoisotopic: 113.047678473
Chemical Formula
C5H7NO2
InChI Key
RHTAIKJZSXNELN-UHFFFAOYSA-N
InChI
InChI=1S/C5H7NO2/c7-5(8)4-2-1-3-6-4/h1-3H2,(H,7,8)
IUPAC Name
3,4-dihydro-2H-pyrrol-1-ium-5-carboxylate
SMILES
[O-]C(=O)C1=[NH+]CCC1

Pharmacology

Indication
Not Available
Structured Indications
Not Available
Pharmacodynamics
Not Available
Mechanism of action
TargetActionsOrganism
UD-amino-acid oxidaseNot AvailableHuman
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
PathwayCategory
D-Arginine and D-Ornithine MetabolismMetabolic
Prolidase Deficiency (PD)Disease
Ornithine Aminotransferase Deficiency (OAT Deficiency)Disease
Arginine and Proline MetabolismMetabolic
Prolinemia Type IIDisease
Hyperprolinemia Type IDisease
Guanidinoacetate Methyltransferase Deficiency (GAMT Deficiency)Disease
Hyperprolinemia Type IIDisease
Arginine: Glycine Amidinotransferase Deficiency (AGAT Deficiency)Disease
Creatine deficiency, guanidinoacetate methyltransferase deficiencyDisease
Hyperornithinemia with gyrate atrophy (HOGA)Disease
Hyperornithinemia-hyperammonemia-homocitrullinuria [HHH-syndrome]Disease
L-arginine:glycine amidinotransferase deficiencyDisease
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
Not Available
Food Interactions
Not Available

References

General References
Not Available
External Links
Human Metabolome Database
HMDB06875
KEGG Compound
C03564
PubChem Compound
440046
PubChem Substance
46504530
ChemSpider
389057
ChEBI
39785
ChEMBL
CHEMBL18591
HET
2PC
PDB Entries
1evi

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility23.6 mg/mLALOGPS
logP0.38ALOGPS
logP0.53ChemAxon
logS-0.85ALOGPS
pKa (Strongest Acidic)3.93ChemAxon
pKa (Strongest Basic)1.72ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area54.1 Å2ChemAxon
Rotatable Bond Count1ChemAxon
Refractivity49.89 m3·mol-1ChemAxon
Polarizability10.81 Å3ChemAxon
Number of Rings1ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9591
Blood Brain Barrier+0.979
Caco-2 permeable-0.5343
P-glycoprotein substrateNon-substrate0.6729
P-glycoprotein inhibitor INon-inhibitor0.9903
P-glycoprotein inhibitor IINon-inhibitor0.9529
Renal organic cation transporterNon-inhibitor0.588
CYP450 2C9 substrateNon-substrate0.8176
CYP450 2D6 substrateNon-substrate0.7103
CYP450 3A4 substrateNon-substrate0.7046
CYP450 1A2 substrateNon-inhibitor0.6586
CYP450 2C9 inhibitorNon-inhibitor0.9297
CYP450 2D6 inhibitorNon-inhibitor0.8842
CYP450 2C19 inhibitorNon-inhibitor0.9282
CYP450 3A4 inhibitorNon-inhibitor0.9843
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9731
Ames testNon AMES toxic0.7938
CarcinogenicityNon-carcinogens0.9414
BiodegradationReady biodegradable0.8771
Rat acute toxicity2.3613 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9454
hERG inhibition (predictor II)Non-inhibitor0.973
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
GC-MS Spectrum - GC-MS (1 TMS)GC-MSsplash10-00di-2900000000-66ac333a416ee8f7a478
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
GC-MS Spectrum - GC-MSGC-MSsplash10-00di-2900000000-66ac333a416ee8f7a478
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as pyrrolines. These are compounds containing a pyrroline ring, which is a five-member unsaturated aliphatic ring with one nitrogen atom and four carbon atoms.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Pyrrolines
Sub Class
Not Available
Direct Parent
Pyrrolines
Alternative Parents
Ketimines / Propargyl-type 1,3-dipolar organic compounds / Monocarboxylic acids and derivatives / Carboxylic acids / Azacyclic compounds / Organopnictogen compounds / Organic oxides / Hydrocarbon derivatives / Carbonyl compounds
Substituents
Pyrroline / Ketimine / Carboxylic acid derivative / Carboxylic acid / Monocarboxylic acid or derivatives / Azacycle / Organic 1,3-dipolar compound / Propargyl-type 1,3-dipolar organic compound / Carbonyl group / Hydrocarbon derivative
Molecular Framework
Aliphatic heteromonocyclic compounds
External Descriptors
1-pyrrolinecarboxylic acid (CHEBI:36761)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Receptor binding
Specific Function
Regulates the level of the neuromodulator D-serine in the brain. Has high activity towards D-DOPA and contributes to dopamine synthesis. Could act as a detoxifying agent which removes D-amino acids...
Gene Name
DAO
Uniprot ID
P14920
Uniprot Name
D-amino-acid oxidase
Molecular Weight
39473.75 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
  3. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235]

Drug created on June 13, 2005 07:24 / Updated on November 09, 2017 03:19